A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer

Bernardo Leon Rapoport, Geoffrey Falkson, Stephen Maxted Ansell, Barend Petrus Lotz, Magriet de Wet

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m2 per day for 5 days, followed by 350 mg/m2 weekly from day 14, plus mitomycin C (MMC) 12 mg/m2 given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.

Original languageEnglish (US)
Pages (from-to)323-328
Number of pages6
JournalLung Cancer
Volume7
Issue number5
DOIs
StatePublished - Oct 1991

Keywords

  • Mitomycin-C
  • Non Small Cell Lung Cancer
  • Suramin

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II clinical study of suramin in combination with mitomycin C in patients with non small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this